MENS News

Jyong Biotech Ltd. Files Annual Report on Form 20-F for Fiscal Year 2025

Jyong Biotech Updates Market Access Strategy for Innovative Botanical Drugs, Establishing Multiple Competitive Advantages for New Drug Portfolio

Jyong Biotech Updates the Potential Clinical Benefits and Advantages of Its Plant-Derived Innovative Drug MCS®-2

Jyong Biotech Reports Transformative Period of Clinical Validation and Commercialization Attempt: Phase II Data Focuses on Dual Therapeutic Potential of MCS-8 in Oncology and Metabolic Health, Alongside Strategic Market Entry into Asia

Jyong Biotech Subsidiary Announces Phase II Clinical Data on Cholesterol and LDH Indicators for MCS-8 (PCP), Indicating Potential in Prostate Cancer Prevention and Metabolic Value

Jyong Biotech Responds to Share Price and Volume Movement

Jyong Biotech Expands Regional Partnerships, Signs MOU with a Vietnam Pharmaceutical Distributor for MCS‑2 Market Entry

Jyong Biotech Ltd. Signs Non‑Binding Letter of Intent with Leading South Korean Pharmaceutical Company to Evaluate In‑Licensing of Plant-Derived MCS Drugs

Jyong Biotech Announces Completion of Primary Endpoint Statistical Analysis for Phase II Clinical Trial of MCS-8 With Positive Outcomes

Jyong Biotech Wins Innovation Gold Award in Pharmaceutical Category at 2025 Taipei Biotech Awards